Acute Respiratory Distress Syndrome - Pipeline Review, H2 2016

Date: July 30, 2016
Pages: 97
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A7655ACCBB1EN
Leaflet:

Download PDF Leaflet

Acute Respiratory Distress Syndrome - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Acute Respiratory Distress Syndrome - Pipeline Review, H2 2016’, provides an overview of the Acute Respiratory Distress Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Respiratory Distress Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Respiratory Distress Syndrome and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Acute Respiratory Distress Syndrome
  • The report reviews pipeline therapeutics for Acute Respiratory Distress Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Acute Respiratory Distress Syndrome therapeutics and enlists all their major and minor projects
  • The report assesses Acute Respiratory Distress Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Acute Respiratory Distress Syndrome
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Acute Respiratory Distress Syndrome
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Acute Respiratory Distress Syndrome pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Acute Respiratory Distress Syndrome Overview
Therapeutics Development
Pipeline Products for Acute Respiratory Distress Syndrome - Overview
Pipeline Products for Acute Respiratory Distress Syndrome - Comparative Analysis
Acute Respiratory Distress Syndrome - Therapeutics under Development by Companies
Acute Respiratory Distress Syndrome - Therapeutics under Investigation by Universities/Institutes
Acute Respiratory Distress Syndrome - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Acute Respiratory Distress Syndrome - Products under Development by Companies
Acute Respiratory Distress Syndrome - Products under Investigation by Universities/Institutes
Acute Respiratory Distress Syndrome - Companies Involved in Therapeutics Development
Altor BioScience Corporation
Athersys, Inc.
Faron Pharmaceuticals Oy
FirstString Research, Inc.
GlaxoSmithKline Plc
Global Blood Therapeutics, Inc.
Hydra Biosciences, Inc.
Phylogica Limited
S-Evans Biosciences, Inc.
Savara Inc.
Silence Therapeutics Plc
Acute Respiratory Distress Syndrome - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ALT-836 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIO-10901 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIO-11006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GBT-440 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2586881 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2862277 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HC-067047 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
interferon beta-1a - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LT-0011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
molgramostim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit uPA for Infectious Disease and Respiratory Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotide to Inhibit Endothelin-1 for CVS, Oncology and Respiratory Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-05285401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PYC-35 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PYC-36 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PYC-38 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PYC-98 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Proteins for Acute Lung Injury and Acute Respiratory Distress Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-1229 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAN-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit MMP and Cytokine for Immunology, Respiratory and Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Acute Respiratory Distress Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Metabolic, Gastrointestinal, Multiple Organ Failure and Respiratory Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide for Acute Lung Injury and Acute Respiratory Distress Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Acute Respiratory Distress Syndrome - Dormant Projects
Acute Respiratory Distress Syndrome - Discontinued Products
Acute Respiratory Distress Syndrome - Product Development Milestones
Featured News & Press Releases
May 25, 2016: First patient dosed in Savaras pivotal trial for PAP
Mar 01, 2016: Faron files patent application to further strengthen protection for its novel Traumakine (FP-1201-lyo) formulation
Jan 07, 2016: Positive top-line results from the Japanese Phase II study of Traumakine for the treatment of ARDS
Dec 29, 2015: First Patient recruited in Pan-European Phase III INTEREST study for treatment of acute respiratory distress syndrome
Oct 19, 2015: Serendex to initiate pivotal phase II/III clinical trial for PAP
Aug 09, 2015: Serendex to initiate first phase II clinical trial
Jun 10, 2015: Recruitment of ARDS patients for Serendex phase II clinical trial to commence in November
May 27, 2015: Phase I clinical trial of inhaled molgramostim has commenced
May 20, 2015: Novozymes Biopharma enables stable formulation of Serendex Pharmaceutical’s inhalable biological drug for treatment of severe pulmonary diseases
May 10, 2015: Positive topline data from Serendex phase I clinical trial
Feb 27, 2015: Serendex submits phase I application
Feb 13, 2015: Serendex partners up with leading German lung center
Jan 28, 2015: Serendex receives positive scientific advice from EMA
Jan 22, 2015: Athersys and Cell Therapy Catapult Announce Grant to Support Clinical Development of Stem Cell Therapy for Severe Acute Respiratory Condition
Dec 10, 2014: Serendex Registers First Sale Of Molgradex
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Acute Respiratory Distress Syndrome, H2 2016
Number of Products under Development for Acute Respiratory Distress Syndrome - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Acute Respiratory Distress Syndrome - Pipeline by Altor BioScience Corporation, H2 2016
Acute Respiratory Distress Syndrome - Pipeline by Athersys, Inc., H2 2016
Acute Respiratory Distress Syndrome - Pipeline by Faron Pharmaceuticals Oy, H2 2016
Acute Respiratory Distress Syndrome - Pipeline by FirstString Research, Inc., H2 2016
Acute Respiratory Distress Syndrome - Pipeline by GlaxoSmithKline Plc, H2 2016
Acute Respiratory Distress Syndrome - Pipeline by Global Blood Therapeutics, Inc., H2 2016
Acute Respiratory Distress Syndrome - Pipeline by Hydra Biosciences, Inc., H2 2016
Acute Respiratory Distress Syndrome - Pipeline by Phylogica Limited, H2 2016
Acute Respiratory Distress Syndrome - Pipeline by S-Evans Biosciences, Inc., H2 2016
Acute Respiratory Distress Syndrome - Pipeline by Savara Inc., H2 2016
Acute Respiratory Distress Syndrome - Pipeline by Silence Therapeutics Plc, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Acute Respiratory Distress Syndrome - Dormant Projects, H2 2016
Acute Respiratory Distress Syndrome - Dormant Projects (Contd..1), H2 2016
Acute Respiratory Distress Syndrome - Dormant Projects (Contd..2), H2 2016
Acute Respiratory Distress Syndrome - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Acute Respiratory Distress Syndrome, H2 2016
Number of Products under Development for Acute Respiratory Distress Syndrome - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Ask Your Question

Acute Respiratory Distress Syndrome - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: